Clinical trial · Interventional
Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor
Tumor Bed Hypofractionated IMRT (VMAT-RA) After Surgical Resection for Patients With Single, Large (≥2.1 cm) Brain Metastases From Solid Tumor
NCT02576522CI-TRIAL-00038793completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigators designed a study of a multimodality approach: surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach for patients with single, large brain metastases from solid primary tumor
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| brain metastatic patients | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- brain metastatic patients
- description
- Patients with single, large brain metastases from solid tumors
- interventionNames
- Radiation: brain metastatic patients
Primary outcomes (1)
- measure
- Local control rate
- timeFrame
- 6 months
Secondary outcomes (5)
- measure
- Distant brain failure
- timeFrame
- 6 months
- measure
- Overall survival, statistical
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Karnosky performance status (KPS) ≥70 * All Solid tumor (esclusion SCLC and Germinal tumors) * Controlled primary tumor * Controlled other metastatic site * Single metastatic lesion at diagnosis * Lesions ≥ 2.1 cm in maximum diameter (4 cm3), \< 3 cm conditioning mass effect or neurological deficits or massive aedema, unknown primary tumor * Estimated survival ≥ 3 months. * Written informed consent Exclusion Criteria: * Prior WBRT * KPS ≤ 70 * Other primary cancer * Pregnant women
References
Publications (0)
Data not yet available
No reference posted for this study.